Hookipa Pharma (NASDAQ:HOOK) Stock Price Down 2.4%

Shares of Hookipa Pharma Inc (NASDAQ:HOOK) dropped 2.4% during trading on Friday . The stock traded as low as $0.55 and last traded at $0.57. Approximately 431,135 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 711,375 shares. The stock had previously closed at $0.58.

Wall Street Analyst Weigh In

HOOK has been the topic of several analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Hookipa Pharma in a report on Tuesday, May 21st. HC Wainwright boosted their price objective on Hookipa Pharma from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th.

Hookipa Pharma Price Performance

The stock’s 50 day simple moving average is $0.77 and its two-hundred day simple moving average is $0.75.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Thursday, May 9th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.24. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. The company had revenue of $36.60 million during the quarter, compared to the consensus estimate of $3.20 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. On average, sell-side analysts anticipate that Hookipa Pharma Inc will post -0.46 EPS for the current year.

Institutional Trading of Hookipa Pharma

A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC bought a new stake in Hookipa Pharma Inc (NASDAQ:HOOK) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 43,021 shares of the company’s stock, valued at approximately $31,000. 63.88% of the stock is owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.